Coordinated Care Management

December 01, 2011

PositiveID's iglucose System Clears FCC Testing

Technological advancements being made everyday are making things better and more convenient for us in every sphere of life, and healthcare is no exception to this. With the help of the latest devices, healthcare professionals are able to assess the medical condition of a patient in a much more accurate way, and similarly provide him with proper and necessary treatment at the right time.

PositiveID Corporation, a provider of advanced medical devices and molecular diagnostic systems that help in diabetes management, rapid medical testing and airborne bio-threat detection, has announced that its new iglucose mobile health device has cleared the testing specified by Federal Communications Commission (FCC).

After successfully meeting the regulatory requirements laid out by the FCC, the iglucose System can now be sold in the U.S. market. Prior to this, the U.S. Food and Drug Administration had cleared PositiveID to market the iglucose System within the nation.

Leveraging mobile technology, iglucose makes the diabetic patients free from the need to keep manual logbooks so that they can manage their condition in a better way. The blood glucose readings are received from data capable glucometers, and are further wirelessly transmitted by the iglucose device to be submitted to the iglucose diabetes management portal. Depending upon the patient’s wish, these glucose readings are automatically sent to his family members, caregivers and healthcare professionals via text message, email or fax.

It helps the patient to keep his near and dear ones constantly aware of his condition, and also receive proper healthcare at lower costs. The iglucose diabetes management portal features various graphs, charts and reports that allow the diabetic patients and their healthcare professionals to consistently keep an eye upon their blood glucose levels plan their diabetes management accordingly. The iglucose device doesn’t need to be connected to a cell phone or a wireless plan for transmitting the data.

“Successfully passing all FCC required testing of iglucose so soon after receiving FDA clearance, we believe, is a testament to our excellent engineering team and device design, which enabled us to pass all certification testing with no redesigns required,” commented William J. Caragol, chief executive officer at PositiveID.

“All wireless communication devices must pass FCC certification prior to commercial launch, and these mandatory regulatory clearances now position us to bring iglucose, a first-of-its-kind product, to market to simplify the lives of individuals with diabetes,” added Caragol.

In March 2011, Sierra Wireless, a provider of products and solutions for mobile computing and wireless machine-to-machine or ‘M2M’ communications, announced that its AirPrime will power PositiveID’s iglucose solution.

Arvind Arora is a contributing editor for HealthTechZone. To read more of Arvind's articles, please visit his columnist page.

Edited by Jennifer Russell
Get stories like this delivered straight to your inbox. [Free eNews Subscription]